VIGL vs. OMGA, LIFE, SGMO, DBVT, BLUE, VXRT, GRTS, MOLN, OTLK, and CRDL
Should you be buying Vigil Neuroscience stock or one of its competitors? The main competitors of Vigil Neuroscience include Omega Therapeutics (OMGA), aTyr Pharma (LIFE), Sangamo Therapeutics (SGMO), DBV Technologies (DBVT), bluebird bio (BLUE), Vaxart (VXRT), Gritstone bio (GRTS), Molecular Partners (MOLN), Outlook Therapeutics (OTLK), and Cardiol Therapeutics (CRDL). These companies are all part of the "biological products, except diagnostic" industry.
Omega Therapeutics (NASDAQ:OMGA) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment, valuation and community ranking.
Omega Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 320.17%. Vigil Neuroscience has a consensus target price of $17.20, indicating a potential upside of 385.88%. Given Omega Therapeutics' higher probable upside, analysts clearly believe Vigil Neuroscience is more favorable than Omega Therapeutics.
97.5% of Omega Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are held by institutional investors. 57.0% of Omega Therapeutics shares are held by company insiders. Comparatively, 33.0% of Vigil Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Omega Therapeutics has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500.
In the previous week, Omega Therapeutics had 1 more articles in the media than Vigil Neuroscience. MarketBeat recorded 21 mentions for Omega Therapeutics and 20 mentions for Vigil Neuroscience. Omega Therapeutics' average media sentiment score of 0.82 beat Vigil Neuroscience's score of 0.62 indicating that Vigil Neuroscience is being referred to more favorably in the news media.
Vigil Neuroscience has a net margin of 0.00% compared to Vigil Neuroscience's net margin of -1,868.35%. Omega Therapeutics' return on equity of -64.96% beat Vigil Neuroscience's return on equity.
Vigil Neuroscience has lower revenue, but higher earnings than Omega Therapeutics. Vigil Neuroscience is trading at a lower price-to-earnings ratio than Omega Therapeutics, indicating that it is currently the more affordable of the two stocks.
Omega Therapeutics received 5 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 75.00% of users gave Vigil Neuroscience an outperform vote while only 71.88% of users gave Omega Therapeutics an outperform vote.
Summary
Omega Therapeutics beats Vigil Neuroscience on 11 of the 17 factors compared between the two stocks.
Get Vigil Neuroscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vigil Neuroscience Competitors List
Related Companies and Tools
